Pfizer Debuts Biosimilar Of Amgen, Janssen Meds
Pfizer Inc. on Wednesday announced the launch of a sharply discounted biosimilar version of Amgen Inc.'s Epogen and Janssen Pharmaceuticals Inc.'s Procrit, capping hard-fought development efforts marked by approval setbacks and...To view the full article, register now.
Already a subscriber? Click here to view full article